Skip to content
Study details
Enrolling now

Pimavanserin for Insomnia in Veterans With PTSD

VA Office of Research and Development
NCT IDNCT05441280ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

60

Study length

about 3.5 years

Ages

18–64

Locations

1 site in TX

About this study

This trial is testing whether pimavanserin helps with insomnia in veterans who also have post-traumatic stress disorder (PTSD). Participants will receive either pimavanserin or a placebo at bedtime for 8 weeks, and their sleep quality will be compared before and after treatment. The goal of it is to understand if pimavanserin can help treat PTSD-related insomnia.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Take pimavanserin
PhasePhase 2
Drugpimavanserin
Routeoral
Primary goalInsomnia Severity Index (ISI)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low12%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

pimavanserin

Drug routes

oral (Oral Capsule)

Endpoints

Primary: Insomnia Severity Index (ISI)

Secondary: PTSD Checklist for DSM-5, Pittsburgh Sleep Quality Index (PSQI)

Body systems

Psychiatry / Mental Health